TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.78M | 23.04M | 390.90M | 28.19M | 5.06M |
| Total Depreciation and Amortization | 32.00K | 21.00K | 17.00K | 13.00K | 8.00K |
| Total Amortization of Deferred Charges | 333.00K | 350.00K | 349.00K | 350.00K | 352.00K |
| Total Other Non-Cash Items | 31.73M | 40.80M | -349.70M | 15.63M | 14.41M |
| Change in Net Operating Assets | -69.76M | -44.54M | -64.71M | -36.74M | -48.54M |
| Cash from Operations | -17.89M | 19.66M | -23.15M | 7.44M | -28.72M |
| Capital Expenditure | -51.00K | -67.00K | -80.00K | -42.00K | -25.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.81M | -15.57M | 46.44M | -3.95M | -12.91M |
| Cash from Investing | -9.86M | -15.64M | 46.36M | -3.99M | -12.93M |
| Total Debt Issued | 747.66M | -- | -- | -- | -- |
| Total Debt Repaid | -255.00M | -- | -- | -- | -- |
| Issuance of Common Stock | 763.00K | 1.06M | 0.00 | 432.00K | 21.00K |
| Repurchase of Common Stock | -99.99M | 0.00 | -78.24M | -6.88M | -6.12M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.60M | -- | -- | -- | -- |
| Cash from Financing | 390.83M | 1.06M | -78.24M | -6.44M | -6.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 363.07M | 5.08M | -55.03M | -3.00M | -47.75M |